Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Por um escritor misterioso
Descrição
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study - The Lancet Oncology
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
Frontiers Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response
COVID-19 vaccines and a perspective on Africa: Trends in Immunology
Covid vaccine efficacy and blood cancer
Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial
Cancer in the Midst of COVID-19, A Report
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies - ScienceDirect
PDF) Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study - eClinicalMedicine
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
Covid-19 Vaccines — Immunity, Variants, Boosters
de
por adulto (o preço varia de acordo com o tamanho do grupo)
